Joseph DeVeaugh-Geiss, who has worked with Voyager Pharmaceutical for the past three years, is the firm’s interim chief medical officer.
DeVaugh-Geiss has been involved in all three phases of trials for Voyager’s drug leuprolide acetate, which is seen as a potential treatment for Alzheimer’s disease.
He has more than 16 years of experience in pharmaceuticals and has been involved in the submission of more than 12 successful new drug applications and supplemental new drug applications.
DeVaugh-Geiss is a former executive at GlaxoSmithKline, where he served as vice president and international director of central nervous system clinical research.
Voyager: www.voyagerpharma.com
